Skip to main content

Market Overview

Pfizer Rebuffs Report On COVID-19 Vaccine Production In South Korea With Samsung BioLogics: Reuters

Share:
Pfizer Rebuffs Report On COVID-19 Vaccine Production In South Korea With Samsung BioLogics: Reuters
  • According to ReutersSamsung BioLogics Co Ltd and Pfizer Inc (NYSE: PFE) have denied reports claiming they were working together to produce the COVID-19 vaccine developed in partnership with BioNTech SE (NASDAQ: BNTX) in South Korea.
  • The Korea Economic Daily reported earlier that the biotech arm of Samsung Group had been revamping production lines at its plant in Songdo to produce the Pfizer/BioNTech vaccine.
  • The report quoted an unnamed high-level government official and said that the plant could make up to 1 billion doses per year, with production starting from August.
  • Samsung BioLogics said in a one-line filing to the stock exchange that the report was "not factual."
  • Pfizer said its current production strategy was centered on its two dedicated supply lines in the U.S. and Europe.
  • "At this time, we are not in discussions for any additional manufacturing outside these established supply lines for this vaccine," Pfizer said in a statement.
  • South Korea has secured 192 million doses, enough to vaccinate all 52 million residents twice over.
  • But President Moon Jae-in is under pressure to secure more and faster deliveries of U.S.-made shots as he heads for his first summit with U.S. President Joe Biden next week. 
  • Price Action: PFE shares are up 0.23% at $39.44 during the premarket session on the last check Wednesday.
 

Related Articles (PFE + BNTX)

View Comments and Join the Discussion!

Posted-In: Briefs COVID-19 VaccineBiotech Government News Health Care Contracts General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com